SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-231557
Filing Date
2023-09-08
Accepted
2023-09-08 16:16:00
Documents
12
Period of Report
2023-09-06
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d532614d8k.htm   iXBRL 8-K 23389
  Complete submission text file 0001193125-23-231557.txt   144599

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tpst-20230906.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20230906_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20230906_pre.xml EX-101.PRE 11265
6 EXTRACTED XBRL INSTANCE DOCUMENT d532614d8k_htm.xml XML 3351
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 231245472
SIC: 2834 Pharmaceutical Preparations